Cellectis

Can CAR T cell therapy tackle solid tumors with precision?   CAR T cell therapy has proven to be lifesaving for many cancer patients. However, its therapeutic efficacy has encountered limited success in solid tumors.   The challenges:   ❌ CAR T cells cannot access their target efficiently due to the suppressive tumor microenvironment (TME)   ❌ Sparse number of tumor-specific antigens, large tumor heterogeneity   How to address these issues:   ✅ Use TALEN® gene editing technology to create “off-the-shelf” CAR T cells that can be engineered to improve persistence, infiltration and overcome the TME common in solid tumors.   ✅ Inducible "IF/THEN-gated" CAR T-cells   Leverage cancer-associated fibroblasts in the tumor microenvironment (TME) as activators. These cells only become fully functional when they encounter specific TME signals, significantly reducing off-target effects and enhancing safety.   ✅ Breaking through the tumor barrier   By replacing a suppressive T cell protein gene with a second CAR targeting tumor-associated proteins, we can create T-cells that can effectively penetrate and combat the hostile tumor microenvironment – a major hurdle in solid tumor treatment.   This approach allows for customization of the CAR T-cells to respond to different antigens and represents a significant leap towards making CAR T-cell therapy a viable and powerful option for solid tumors. To know more, read the article: https://lnkd.in/exyTMHfs Thoughts? ↪️

This World Cancer Day, let's challenge preconceptions about allogeneic CAR-T cell therapy for blood cancers: 🏹 Myth: Less effective than autologous CAR-T cells. ✅ Reality: Allogeneic CAR-T cells are engineered with high precision to target cancer cells effectively, offering comparable specificity and potency. 🏹 Myth: Take too long to develop. ✅ Reality: Allogeneic CAR-T cells are pre-manufactured and immediately available, reducing critical treatment delays. 🏹 Myth: High risk of graft-versus-host disease (GvHD). ✅ Reality: Innovative gene editing technologies, such as TCR knockout, have significantly reduced the risk of GvHD, making allogeneic CAR-T cells safer to patients. 🏹 Myth: Relapse rates are higher. ✅ Reality: Ongoing innovations in cell durability and persistence are improving long-term outcomes, showing promise in reducing relapse rate. We're committed to developing innovative allogeneic CAR-T cell therapies, uniting cutting-edge science with unique patient needs. Together, we can reimagine cancer care. #WorldCancerDay2025 #UnitedByUnique

❌ The perfect murder: how immune cells eliminate threats? ❌   Imagine your body as a city with immune cells as security forces: 🕵 Macrophages = Detectives who patrol the streets and identify suspicious individuals (antigens) 👮 T-cells = special force unit, who recognize the threat and spring into action. ❗The Call to Action: The macrophage presents the "wanted” antigen to T-cells. The T-cells carefully examine it and decide whether it's a genuine threat. 💡 T-Cell Activation: Once a T-cell confirms the danger, it transforms into an active defender, ready to neutralize the threat. However, sometimes this means turning on the very detective (macrophage) that presented the information—especially if the macrophage has been compromised by the intruder. ❌ Macrophage Sacrifice: To prevent the spread of hidden enemies or overreaction, T-cells may induce apoptosis (programmed cell death) in the macrophage, a necessary sacrifice to protect the city from further harm. ♻️ Recycling and Renewal: Afterward, cleanup crews (healthy macrophages) step in to recycle the remains of the sacrificed cells. This ensures no harmful debris is left behind, keeping the city's streets clean and ready for future challenges. This dance of detection, activation, sacrifice, and renewal is what keeps our immune system functioning like a well-oiled machine, ensuring our body's "city" remains safe and healthy. Thanks again to Nanolive SA for the great video!

On this Martin Luther King Jr. Day, we are reflecting on how we can create positive change in our own spheres of influence - whether through small daily actions or bold, transformative steps.   We believe in the transformative power of ideas and the importance of perseverance in the face of challenges. Martin Luther King Jr.’s dream wasn't just about equality, but about building a society of understanding and opportunity for all.   As we honor Dr. King's legacy, let's continue to push the boundaries of what's possible in biotechnology. We aim to create a healthier world for all.

We are excited to announce that we will attend the J.P. Morgan Healthcare Conference next week in San Francisco (CA)!   Andre Choulika Ph.D. (CEO), Arthur Stril (CBO & CFO) and Dr. Adrian Kilcoyne MD MPH MBA (CMO) are looking forward to connecting with industry leaders, partners, and colleagues to share insights into our progress and outlook. #JPM25

In 2025, we're not just doing research – we're rewriting the future of medical science. Our passion, dedication, and innovative spirit continue to push the boundaries of what's possible. Every breakthrough, every hard-worked moment, every moment of scientific curiosity brings us closer to our ultimate goal: giving hope and new possibilities to patients and families fighting cancer. To our incredible followers and supporters: happy new year and thank you for being part of this transformative journey!

From all of us at Cellectis, we wish you a joyous holiday season! May this festive period bring you moments of joy, reflection, and well-deserved rest. As we look ahead to the New Year, we're filled with optimism for the groundbreaking advancements we'll achieve together in our mission to transform the lives of patients with blood cancers. #HappyHolidays

What if we turn our immune system into cancer killing commandos? Cancer is a nasty disease – it involves the uncontrolled proliferation of abnormal cells that can invade and spread throughout the body, disrupting normal organ function. What if instead of using chemicals, we use our immune system – our T cells - to hunt the cancer cells inside the body? Our battle plan: 1 - Collect T-cells from healthy donor 2 - Genetically modify the T-cells using TALEN® gene editing technology to target cancer cells 3 - Create an army of specialized cancer-targeting T-cells 4 - Deploy the killer cells against tumors in the body Why it’s a good plan? ✅ Safe, precise, efficient : TALEN® is one of the most precise tool existing in the gene editing field ✅ The CAR T-cells are manufactured internally from A to Z to ensure consistency and quality control ✅ One donor, multiple patients: the off-the-shelf approach allows to treat numerous patients with cells from a single healthy donor, maximizing efficiency and reach. ✅ Off-the-shelf therapy ready to deploy immediately, potentially saving crucial time for patients who need immediate treatment. It's the future of cancer treatment - where we don't just fight cancer, we precisely target and eliminate it. Thanks TEDxSaclay for reposting this video archive! Link to watch the TEDx video: https://lnkd.in/eVz6BnYp

Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB). To read the press release: https://lnkd.in/e8B3tbDs

Pourquoi la thérapie génique est-elle la médecine du futur ?  Dans cette deuxième vidéo, Andre Choulika Ph.D., directeur général de Cellectis, partage sa vision sur les perspectives d’avenir qu’offrent les thérapies géniques et nous explique comment cette nouvelle approche, longtemps fantasmée, devient réalité.  Désormais capable de réparer des gènes défectueux et de détruire les cellules cancéreuses, la thérapie génique offre de nouvelles solutions pour des patients sans traitement jusqu’alors et dans de nombreux domaines thérapeutiques : l’oncologie, l’immunologie, la neurologie, et les maladies rares ou orphelines. Les principaux enjeux selon lui ? La sécurité des traitements et la capacité de cibler précisément les bons tissus ou organes pour garantir une efficacité optimale.